BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company specializing in antibody-drug conjugate therapeutics for challenging cancer treatments, has announced the approval of stock options for four newly hired employees. According to Pyxis Oncology's Compensation Committee, the stock options collectively allow for the purchase of 246,238 shares of common stock under the 2022 Inducement Plan. These options were granted as part of the hiring agreements with a grant date of June 30, 2025, and are compliant with Nasdaq Listing Rule 5635(c)(4). Of the total, 181,238 options will vest over four years, with an initial 25% vesting after one year and the remainder vesting monthly over a subsequent 36-month period. Additionally, 65,000 options are set to vest fully by December 31, 2025, contingent on continued employment. The options have a ten-year term, with an exercise price of $1.10, matching the closing price of the company's stock on the grant date.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.